JZP926 capsule for myoclonic epilepsy, juvenile

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Jul 2026: Trial registered, NCT07723963
  2. 18 Sep 2026: Trial started, NCT07723963

The trials

NCT07723963: A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

State
Under way
Phase
Phase 2 and Phase 3
People
260 planned
Started
18 Sep 2026
Primary completion
1 Aug 2028
Arms
JZP926 Capsule, Open-Label Extension: JZP926 Capsule
Results
None posted
  1. 23 Jul 2026: Trial registered
  2. 18 Sep 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.